Design Strategies for Hyaluronic Acid-based Drug Delivery Systems in Cancer Immunotherapy.
(2025) Journal of Controlled Release — Vol. 383, p. 113784 (2025)
Files
JControlRelease2025-383-113784.pdf
Open Access - Adobe PDF
- 6.59 MB
Details
- Authors
- Abstract
- Despite its robust therapeutic potential, cancer immunotherapy has provided little progress towards improved survival rates for patients bearing immunologically refractory tumors. The implementation of advanced drug delivery systems represents a powerful means of improving cancer immunotherapy by relieving immunosuppression and promoting immune response; however, the overall impact of these systems on immunotherapy currently remains modest. Hyaluronic acid represents a widely used polymer in drug delivery; meanwhile, recent studies linking hyaluronic acid to the immune system make this polymer an attractive component in the design of next-generation cancer immunotherapies. Herein, we review our current understanding of the immunological properties of hyaluronic acid and discuss them in the context of bioactive functions and immune-related interactions with receptors, immune, and cancer cells. We analyze the potential of hyaluronic acid as a component in advanced drug delivery systems, highlighting strategies for the design of more effective vaccines and cancer chemo-immunotherapies. Finally, we discuss critical considerations to facilitate design and clinical translation to overcome existing challenges and maximize therapeutic potential.
- Affiliations
Citations
Rodella, G., Préat, V., Gallez, B., & Malfanti, A. (2025). Design Strategies for Hyaluronic Acid-based Drug Delivery Systems in Cancer Immunotherapy. Journal of Controlled Release, 383, 113784. https://doi.org/10.1016/j.jconrel.2025.113784 (Original work published 2025)